Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase 1/2a Study of K-1728 in Advanced Solid Tumors
Sponsor: KymaThera, Inc.
Summary
This first-in-human, open-label, multicenter study evaluates K-1728 administered as monotherapy and in combination in participants with advanced or metastatic solid tumors. The study assesses the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of K-1728.
Official title: A First-in-Human Study of K-1728 Administered Alone and in Combination in Participants With Advanced or Metastatic Solid Tumors
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
110
Start Date
2026-10
Completion Date
2029-03
Last Updated
2026-10-06
Healthy Volunteers
No
Interventions
K-1728
K-1728 will be administered orally once daily in 28-day cycles
Fulvestrant
Fulvestrant will be administered intramuscularly on Days 1 and 15 of Cycle 1, and then Day 1 of each subsequent 28-day cycle
Palbociclib
Palbociclib will be administered orally on Days 1-21 in 28-day cycles